Type III-A Csm Complex RNA Knockdown in Vertebrates

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current CRISPR-Cas systems, particularly Type III-A Csm complexes, face challenges in demonstrating DNA degradation activity and require reconstitution in vitro, with limited understanding of their function and mechanism, especially in vertebrates for RNA knockdown applications.

Innovation Solution

The Streptococcus thermophilus Type III-A Csm complex, comprising crRNA, Csm4, and Csm3, is used for targeted RNA cleavage in vertebrates, demonstrating RNA knockdown capabilities by introducing multiple cuts at regular intervals, and the minimal complex composition required for RNA degradation is established, allowing for programmable RNA interference-like methods.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If Type III-A Csm complex is used for RNA knockdown in vertebrates, then RNA degradation capability is improved, but the complexity of reconstitution and mechanism understanding remains limited

Engineering Contradiction:
ImproveRNA knockdown efficacyVSAvoidComplex reconstitution requirement
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts and identifies the minimal functional components of the Type III-A Csm complex required for RNA degradation activity. By determining that Csm3, Csm4, and crRNA constitute the minimal complex, the invention simplifies the system while maintaining RNA knockdown efficacy in vertebrates, reducing the complexity of reconstitution.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention changes the parameter of complex composition by identifying and isolating specific subunits (Csm3, Csm4) and their stoichiometric ratios required for RNA degradation. This parameter optimization allows effective RNA knockdown with a simplified complex composition, resolving the contradiction between efficacy and reconstitution complexity.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If traditional RNA interference methods are used, then RNA knockdown is achieved, but efficacy is limited in certain organisms

Engineering Contradiction:
ImproveRNA knockdown efficacyVSAvoidOrganism applicability
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies the Type III-A Csm complex, originally from bacterial systems, to RNA knockdown in vertebrates. This cross-kingdom application demonstrates the universal functionality of the Csm complex mechanism across different organisms, overcoming the limitations of traditional RNAi methods that are organism-specific.

Inventive Principle:
Principle #6Universality (Multi-functionality)

Solution Approach 2:

The invention replaces the traditional RNA interference mechanism (Dicer-dependent pathway) with the CRISPR-Cas derived Csm complex mechanism (CRISPR RNA-guided cleavage). This substitution provides a novel molecular mechanism that achieves RNA knockdown with broader organism applicability, including vertebrates where traditional RNAi is less effective.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach provides a novel tool for site-specific RNA degradation or modification, enabling effective RNA knockdown or knock-out in vertebrates, offering an alternative to traditional RNA interference methods and overcoming limitations in RNAi efficacy in certain organisms.

Implementation Method 1

using crRNA as a guide, locates and degrades the target NA

Methodology Applied
Scientific EffectBase pairing:

Implementation Method 2

The Csm3 protein, present in multiple copies in both Csm complexes, acts as endoribonuclease

Methodology Applied
Scientific EffectEnzymatic cleavage: Enzyme

Implementation Method 3

Both complexes targeted RNA and generated multiple cuts at 6 nucleotide (nt) intervals

Methodology Applied
Scientific EffectRNA cleavage:

Data Source

PatentUS11274317B2Targeted RNA knockdown and knockout by type III-A Csm complexes
Publication Date: 2022.03.15 VILNIUS UNIV
  • US11274317B2 patent drawing
  • US11274317B2 patent drawing
  • US11274317B2 patent drawing

AI summary

Methods and compositions using a CRISPR-Cas Type IIIA resulting in RNA gene knockdown and knockout in an animal.